Loading…
Loading…
Halter Ferguson Financial Inc. trimmed its position in Eli Lilly and Company (NYSE: LLY) by 90.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 814 shares of the company's stock after selling 7,473 shares during the
Crossmark Global Holdings Inc. increased its stake in Eli Lilly and Company (NYSE: LLY) by 5.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 46,657 shares of the company's stock after purchasing an additional 2,507 shares during the period. Eli Lilly and Company
Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026PR NewswireINDI
Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FR α expression levels Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy Sofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol INDIANAPOLIS, Oct. 24, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive ovarian cancer (PSOC). A cORR of 79% or higher was seen in both poly (ADP-ribose) polymerase inhibitor (PARPi)-treated and PARPi-naïve patients.
Eli Lilly chair and CEO Dave Ricks discusses the company's expansion and 150th year in business on ‘Claman's Power Players.' #fox #foxbusiness #media #breakingnews #us #usa #new #news #breaking #clamanspowerplayers #lizclaman #claman #elililly #davericks #ricks #weightloss #weightlossdrugs #obesity #obesitytreatment #glp1 #pharmaceuticals #pharma #pharmaceuticalindustry #healthcare #healthcareinnovation #drugdevelopment #artificialintelligence #ai #aitechnology #biotech #biotechnology #medicalresearch #medicine #business #businessnews #innovation #technology #drugdiscovery #healthtech #ceo #corporateexpansion